Practice Variations in the Management of Clostridioides difficile Infection: Findings From a Survey of US Physicians Authors: Abhishek Deshpande, Elizabeth L. Hohmann, Chelsea Burns, Nicholas J. Tomeo, Jessica R. Allegretti Published: 2026 ABSTRACT Background and AimsIn 2021, the American College of Gastroenterology and Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America released guidelines for Clostridioides difficile infection (CDI) management, with conflicting recommendations. We surveyed US gastroenterologists (GIs), infectious disease (ID) specialists, and primary care physicians (PCPs) on their use of clinical guidelines and attitudes toward gut microbial therapies for CDI.MethodsWe conducted an online survey of 302 physicians (n = 101 GIs, 101 IDs, 100 PCPs; February 24 to March 13, 2023). Included GIs and IDs saw a minimum of 3 to 4 patients and PCPs 1 to 2 patients with CDI per month.ResultsPhysicians working in hospital/academic settings were more familiar with CDI guidelines than those working in independent/group practices. Half of GIs used American College of Gastroenterology guidelines; 98% of IDs followed Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines. More PCPs reported that their institutions did not have set guidelines (40%). More GIs (51%) and IDs (74%) used the recommended multistep algorithm for CDI testing; PCPs were more likely to use a single diagnostic test (49%). GIs and IDs more often prescribed vancomycin taper (93% and 98%, respectively) and fidaxomicin (87% and 97%, respectively); PCPs were more likely to prescribe metronidazole (84%). Less than 10% of physicians felt very knowledgeable about donor-derived microbiome therapies. While 60% of GIs, 53% of IDs, and 50% of PCPs agreed donor-derived microbiome therapies are essential for CDI management, more than 50% cited the need for real-world evidence of safety and efficacy.ConclusionEducation around CDI guidelines and standardized diagnostic and treatment algorithms are needed to ensure consistent CDI management. Introduction Clostridioides difficile infection (CDI) is considered one of the top 5 urgent public health threats by the US Centers for Disease Control and Prevention.1 In 2019, CDI was responsible for approximately 223,900 hospitalizations and 12,800 deaths in the United States; in 2017, CDI management led to an estimated $1 billion in health-care costs.2 Though health care–associated cases are declining, CDI remains the most common infection in hospital settings, and both community-acquired infections and recurrent infections are increasing.3 Patients with CDI are seen by physicians from several specialties and in various health-care settings including hospitals, long-term care facilities, and community practices. Two sets of clinical practice guidelines for C difficile infection exist in the US, one from the American College of Gastroenterology (ACG)4 and one collaborative guideline from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America (IDSA/SHEA).5 Conflicting recommendations in these guidelines may lead to inconsistencies in how physicians across specialties and settings approach the diagnosis and management of CDI. For example, discordance regarding the appropriate use of highly sensitive nucleic acid amplification tests (NAATs) in combination with other diagnostic tests, such as enzyme immunoassays4,6 can lead to diagnostic inconsistencies and inappropriate antibiotic use. In addition, updates in the IDSA/SHEA guidelines introduced discrepancies over the preferential use of certain antibiotics.5 In 2022 and 2023, the US Food and Drug Administration approved the use of 2 donor-derived microbiome therapeutics for the prevention of recurrent CDI, expanding available treatment options; however, it is unclear how these new therapies fit into current clinical practice or existing guideline recommendations. To better understand these challenges, we conducted a national survey evaluating CDI management practices among gastroenterologists (GIs), infectious disease (ID) specialists, and primary care physicians (PCPs) in the US who regularly care for patients with CDI. Our objectives were to (1) assess adherence to current clinical practice guidelines across specialties, (2) evaluate diagnostic and therapeutic decision-making patterns, (3) examine cross-specialty referral practices, and (4) assess familiarity with and attitudes toward emerging microbiome-based therapies for CDI. Characterizing these practice patterns and identifying areas of inconsistency are important first steps toward developing more standardized, evidence-based approaches for the management of CDI. Methods Study Design We developed and fielded a cross-sectional, national survey of US physicians between February 24 and March 13, 2023, in collaboration with PSB Insights (Washington, DC). Responses were anonymous and are reported in aggregate. Participant Selection and Recruitment Using stratified random sampling, we recruited physicians from 3 specialties and we established minimum monthly patient volume thresholds for inclusion to ensure adequate clinical experience with CDI management as follows: ≥3 to 4 CDI patients for GI and ID specialists, and ≥1 to 2 CDI patients for PCPs. Additional inclusion criteria were board certification in the respective specialty, active medical license in the United States, current clinical practice with CDI patients, and English language proficiency. Survey Development The survey instrument was developed through a multistep process. An expert panel of physician specialists first generated initial survey items based on clinical experience and research objectives. The survey was then refined based on feedback and expert review. The final 25-minute survey instrument comprised items across the following six key domains: practice demographics and characteristics, CDI diagnostic approaches, treatment patterns, guideline familiarity and adherence, cross-specialty referral practices, and knowledge of and attitudes toward gut microbial therapies (GMTs). The full set of survey questions and answer selections, as well as the number of respondents for each, are provided in the Supplementary Materials, Supplementary Table 1. Of note, in the survey accessed by health-care providers, microbiome therapeutics was referred to as live biotherapeutic products or LBPs. Following the survey’s completion, it became apparent that LBP was inappropriate terminology for the recently FDA-approved products to prevent CDI recurrence7 and we chose to use the term “donor-derived microbiome therapeutics” to refer to the FDA-approved fecal microbiota live-jslm (a donor stool-derived microbiota suspension, formerly RBX2660)8 and fecal microbiota spores live-brpk (a donor stool-derived spore suspension, formerly SER-109),9 as well as a similar product (CP10110) that was in active clinical trials at the time of the survey. VE303 was also included in the survey and referenced as an LBP.11 Survey Administration The survey was administered by PSB Insights (Washington, DC) through the Forsta platform (FocusVision Decipher at the time of the survey; Forsta, Vancouver, BC, Canada) using standardized protocols. Participants were identified and contacted via email through a prerecruited panel of health-care providers targeting respondents matched to the survey criteria, including physicians segmented by specialty. PSB Insights also engaged their trusted and vetted panel partners to identify additional participants to reach the desired sample size without compromising the inclusion criteria. Three reminder emails were sent to nonrespondents at 1-week intervals. Respondents received compensation for survey completion according to standard panel practices. Statistical Analysis Survey responses were collected anonymously and analyzed using descriptive statistics, with results stratified by physician specialty (G.I., I.D., and P.C.P.) and practice setting (hospital/academic center vs individual/group practice). Categorical variables were summarized as frequencies and percentages. Continuous variables were presented as means with standard deviations or medians based on distribution normality. Comparisons between specialties and practice settings were performed using column proportions testing calculated using the Quantam formula which uses a special case of the t-test where the data in rows and columns being tested are coerced to follow a Bernoulli distribution and assumed to follow a binomial probability distribution. For questions regarding guideline familiarity and treatment effectiveness, responses were analyzed on a 4-point Likert scale (very familiar/effective, somewhat familiar/effective, not that familiar/effective, not at all familiar/effective). For analysis, “very” and “somewhat” responses were combined to calculate the proportion of physicians indicating any level of familiarity or effectiveness. All analyses were conducted using a custom data aggregation platform based in R (DataR, version 2.0.3). Statistical significance was set at P < .05. No adjustments were made for multiple comparisons given the descriptive nature of the study. Results Study Population and Practice Setting Of 433 physicians who responded to the survey invitation, 302 completed the survey (70%), with equivalent specialist numbers represented in the survey population (n = 101 GIs, 101 IDs, and 100 PCPs; Supplementary Table 1). The majority of respondents were male (75%) and White (62%). Respondents were evenly distributed across age groups. Practice settings differed significantly among specialties (P < .001), with IDs predominantly working in hospital/academic settings (74%), while GIs and PCPs were more likely to practice in individual/group settings (61% and 69.0%, respectively). Geographic distribution was reasonably balanced (Northeast: 27%, Midwest: 21%, South: 31%, West: 21%). Diagnostic Approaches and Barriers Diagnostic approaches and risk assessment for CDI varied by specialty. When evaluating patients with suspected CDI, respondents prioritized recent antibiotic use, prior history of CDI, and recent hospitalization as key risk factors (Supplementary Figure 1A). Risk factor assessment also revealed specialty-specific patterns as follows: GIs were more likely to consider a history of ulcerative colitis (89%) or Crohn’s disease (88%) compared to other specialists, while IDs and PCPs emphasized prior CDI history (98% and 85%, respectively) and recent antibiotic exposure (94% and 93%, respectively) (Supplementary Table 1). Regarding diagnostic challenges, specialists identified asymptomatic C difficile colonization as the primary barrier (GI: 71%, ID: 79% vs PCP: 45%, P < .001; Figure 1), while GIs less frequently cited the challenge of distinguishing CDI from other causes of diarrhea (47% vs ID: 64% and PCP: 63%, P = .24). Physicians across specialties consistently identified diarrhea and abdominal pain or cramping as the primary symptoms prompting consideration of a diagnosis of CDI (Supplementary Figure 1B).Figure 1Physician-reported barriers to effective diagnosis of Clostridioides difficile infection (CDI). Respondents were asked, “In your experience, what are the biggest barriers to the effective diagnosis of CDI?” (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Physician-reported barriers to effective diagnosis of Clostridioides difficile infection (CDI). Respondents were asked, “In your experience, what are the biggest barriers to the effective diagnosis of CDI?” (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Referral Patterns Analysis of referral patterns revealed that PCPs were more likely to refer CDI patients (50% reporting “sometimes” or “always”) compared to specialists (GI: 9%, ID: 12%, P < .001). Among referring PCPs (n = 93), 57% preferred GI referrals over ID (43%; Figure 2). The primary reasons for referral differed by specialty, with PCPs most commonly referring for antibiotic advice (34%, n = 17/50), colonoscopy or other diagnostic procedures (32%, n = 16/50), or fecal microbiota transplantation (FMT; 26%, n = 13/50). For PCPs who refer patients to GIs specializing in CDI, the primary reason was for FMT (50%, n = 4/8).Figure 2Physician referral patterns for patients with Clostridioides difficile infection (CDI). Respondents were asked “To which of the following doctors or specialists do you most often refer patients with a CDI?” (N = 184 referring physicians; gastroenterologists n = 47; infectious specialists n = 44; primary care n = 93). Physician referral patterns for patients with Clostridioides difficile infection (CDI). Respondents were asked “To which of the following doctors or specialists do you most often refer patients with a CDI?” (N = 184 referring physicians; gastroenterologists n = 47; infectious specialists n = 44; primary care n = 93). Most IDs indicated FMT as the most common reason they referred patients with CDI to GIs, both those who specialize in CDI (77%, n = 20/26) and general GIs (72%, n = 13/18). Among GIs, the most common reason for referral of a patient with CDI to an ID was for additional advice on antibiotics (42%, n = 17/40). It was less common for a GI to refer patients to an ID for FMT (25%, n = 10/40). Guideline Familiarity and Use Practice setting significantly influenced guideline familiarity, with hospital or academic center physicians reporting higher familiarity with clinical practice guidelines for the management of CDI than those working in independent or group practices (Figure 3A and B). GIs tended to be more familiar with ACG guidelines4 and IDs more familiar with IDSA/SHEA guidelines.5 Reflecting this trend, half of GIs (50%) reported that they follow ACG guidelines, whereas nearly all IDs (98%) reported following IDSA/SHEA guidelines (Figure 3C).Figure 3Familiarity and use of clinical practice guidelines for the management of Clostridioides difficile infection (CDI). (A, B) Respondents were asked, “How familiar are you with each of the following CDI guidelines? (N = 302; gastroenterology n = 101; infectious disease n = 101; primary care n = 100), for the ACG guidelines (Kelly et al., 2021) (A) or IDSA/SHEA guidelines (Johnson et al., 2021) (B). Bars show the percentage of respondents indicating they were “very familiar” or “somewhat familiar” with the indicated guidelines. (C) Respondents with set hospital/practice guidelines for CDI diagnosis and/or testing were asked, “Which standards or guidelines does your practice/hospital follow for your CDI patients? Select all that apply.” Note that 12% of respondents selected “Other,” None of the above,” or “Don’t know” (N = 110; gastroenterologists n = 30; infectious disease n = 55; primary care n = 25). Familiarity and use of clinical practice guidelines for the management of Clostridioides difficile infection (CDI). (A, B) Respondents were asked, “How familiar are you with each of the following CDI guidelines? (N = 302; gastroenterology n = 101; infectious disease n = 101; primary care n = 100), for the ACG guidelines (Kelly et al., 2021) (A) or IDSA/SHEA guidelines (Johnson et al., 2021) (B). Bars show the percentage of respondents indicating they were “very familiar” or “somewhat familiar” with the indicated guidelines. (C) Respondents with set hospital/practice guidelines for CDI diagnosis and/or testing were asked, “Which standards or guidelines does your practice/hospital follow for your CDI patients? Select all that apply.” Note that 12% of respondents selected “Other,” None of the above,” or “Don’t know” (N = 110; gastroenterologists n = 30; infectious disease n = 55; primary care n = 25). Testing Procedures More than 70% of physicians reported that their practice’s CDI diagnostic testing procedures are determined by standards published in the literature and clinical guidelines, as well as assessment of individual patient status and symptoms (Supplementary Figure 2). When asked about institutional CDI testing guidelines, most specialists reported having either “required” (mandatory protocols) or “recommended” (suggested but not mandatory) guidelines in place (IDs: 90% [54% required, 36% recommended]; GIs: 80% [30% required, 50% recommended]). In contrast, PCPs were least likely to report required guidelines (25%), with 40% reporting no set guidelines at their institutions (Figure 4).Figure 4Institutional requirements for Clostridioides difficile infection (CDI) testing procedures. Respondents were asked, “When thinking about guidelines around CDI diagnostics and/or testing for patients, which of the following best describes your practice or hospital?” (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Institutional requirements for Clostridioides difficile infection (CDI) testing procedures. Respondents were asked, “When thinking about guidelines around CDI diagnostics and/or testing for patients, which of the following best describes your practice or hospital?” (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Current guidelines recommend multistep testing algorithms for accurate CDI diagnosis4, 5, 6; however, IDSA/SHEA guidelines allow for NAAT-only testing if institutional criteria for patient stool submission are in place and followed.5,6 Use of multistep algorithms for diagnosing CDI were more common among specialists (GI: 51.5%, ID: 74.3%) than PCPs (30.0%, P < .001). Most respondents (GIs: 54%, n = 15/28; IDs: 71%, n = 37/52; PCPs: 81%, n = 13/16) noted that they would consider treating a patient with a positive NAAT result but a negative enzyme immunoassay result for toxin A/B. For patients with this discordant test result, most IDs indicated that they would rely primarily on their clinical judgment when deciding whether to initiate treatment for CDI (Supplementary Figure 3). PCPs were most likely to consider whether or not the patient was on concurrent antibiotic treatment in deciding whether to initiate CDI treatment. GIs indicated that, for a patient with NAAT positive and toxin A/B negative results, their decision to start treatment would rely on clinical judgment and the patient’s history of organ transplantation or immunocompromised status, and whether the patient was in an intensive care unit setting. Treatment Treatment preferences showed marked variation by specialty. GI and ID respondents had the most experience prescribing vancomycin taper (93% and 98%, respectively) compared to PCPs (62%, P < .001). Similarly, fidaxomicin prescribing was more common among specialists (GI: 87%, ID: 97%) than PCPs (53%, P < .001). Conversely, PCPs more frequently prescribed metronidazole (84%) compared to GIs (62%) and IDs (73%, P < .001). This high rate among PCPs likely reflects the general prescribing pattern rather than for severe/fulminant disease. Consistent with their current practice, most GIs and IDs indicated they were likely to prescribe vancomycin taper and fidaxomicin in the future, and 75% of PCPs indicated that they were likely to prescribe metronidazole. Likewise, respondents agreed that vancomycin taper and fidaxomicin are effective treatments for managing CDI. Notably, all physicians viewed FMT as the most effective treatment for recurrent CDI, with 75% of specialists and 52% of PCPs reporting that it is “very effective” (Figure 5). Regarding biologic therapies, perceived efficacy was low, with only 32% of GIs, 29% of IDs, and 17% of PCPs rating adjunctive bezlotoxumab as ‘very effective’ (Figure 5). Furthermore, the majority of physicians reported that their treatment protocols change based on the severity of CDI and for those with recurrent CDI (Supplementary Figure 4).Figure 5Physician perceptions of treatment efficacy for Clostridioides difficile infection (CDI). Respondents were asked, “How effective are each of the following for managing CDI?” The percentages indicating each treatment was “very effective” are presented (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Physician perceptions of treatment efficacy for Clostridioides difficile infection (CDI). Respondents were asked, “How effective are each of the following for managing CDI?” The percentages indicating each treatment was “very effective” are presented (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Fecal Microbiota Transplantation and Donor-Derived Microbiome Therapeutics FMT is used to prevent CDI recurrence. While FMT is not FDA-approved for any purposes, providers may still use FMT with patient and donor consent when the donor is known to the physician and the stool is appropriately screened and tested.12 Nearly all GIs (97%) and IDs (99%) and 81% of PCPs indicated that they are familiar with FMT (Figure 6), and 83% of GIs and 84% of IDs had experience recommending FMT.Figure 6Familiarity with gut microbial therapies for the prevention of Clostridioides difficile infection (CDI). Respondents were asked, “How familiar are you with the following treatments for preventing CDI recurrence (excluding probiotics)?” The percentages indicating they are “very familiar” or “somewhat familiar” are presented (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). Familiarity with gut microbial therapies for the prevention of Clostridioides difficile infection (CDI). Respondents were asked, “How familiar are you with the following treatments for preventing CDI recurrence (excluding probiotics)?” The percentages indicating they are “very familiar” or “somewhat familiar” are presented (N = 302; gastroenterologists n = 101; infectious disease n = 101; primary care n = 100). By contrast, familiarity with donor-derived microbiome therapeutics was considerably lower than for FMT and varied significantly across specialties. GMTs encompass products made with live microorganisms that lack precise characterization, for example, those prepared from human stool. GMTs include conventional FMTs and donor-derived microbiome therapeutics. At the time of the survey, the first donor-derived microbiome therapeutics for preventing recurrent CDI had been FDA-approved for less than 3 months. Less than 10% of physicians surveyed were “very knowledgeable” about donor-derived microbiome therapeutics (GI: 9%, ID: 8%, PCP: 2%, P = .12). Respondents were most familiar with RBX2660.8 Comfort with prescribing donor-derived microbiome therapeutics was higher among specialists (GI: 66%, ID: 55%) compared to PCPs (49%, P = .02). This comfort level was lower than that reported for using FMT for CDI (GIs: 90%, IDs: 81%, PCPs: 61%). Relative to other physicians, GIs were the most likely to have already prescribed commercially developed donor-derived microbiome therapeutics (GIs: 40%; IDs: 27%; PCPs: 21%). By comparison, 68% of physicians reported prescribing FMT, also primarily GIs (84%). Half (51%) of physicians reported exposure to information on donor-derived microbiome therapeutics from journals or scholarly articles. Physicians who expressed more comfort with donor-derived microbiome therapeutics as a treatment option also reported having had greater exposure to content on the subject (Supplementary Figure 5). When asked what information would improve their comfort with donor-derived microbiome therapeutics as a treatment option for CDI, a majority of physicians cited the need for more real-world data on safety and efficacy and published clinical guidelines from professional societies. Physicians also consistently noted the potential cost to patients as a barrier to prescribing commercial donor-derived microbiome therapeutics for CDI. Despite a need for more information and guidance, 60% of GIs, 53% of IDs, and 50% of PCPs agreed with the statement that donor-derived microbiome therapeutics “are essential to the future of CDI management.” GIs were also more likely than IDs or PCPs to consider off-label use of donor-derived microbiome therapeutics, specifically for the treatment of irritable bowel syndrome, Crohn’s disease, and ulcerative colitis (Supplementary Figure 6). Both IDs and PCPs indicated an interest in the use of donor-derived microbiome therapeutics for the primary prevention of CDI and eradication of multi–drug-resistant organisms. Discussion In this national survey of US GIs, ID specialists, and PCPs who treat patients with CDI, we found distinct differences regarding diagnostic approaches, adherence to clinical practice guidelines, testing approaches, and knowledge gaps about emerging therapies. We found that CDI diagnosis is complicated by asymptomatic C difficile colonization, limited diagnostic accuracy with available laboratory tests, and overlapping symptoms with other GI conditions. Distinguishing true infection from colonization remains a critical challenge. Asymptomatic carriage of toxigenic C difficile is reported to occur in 4% to 15% of the general adult population, with higher rates in hospitalized patients (up to 21%) and long-term care facility residents (up to 30%).4 To avoid overdiagnosis, current guidelines recommend testing only symptomatic patients (3 or more unformed stools in 24 h).4, 5, 6 Providers must consider the sensitivity, specificity, and positive and negative predictive values of available laboratory tests. No single test is sufficient to diagnose CDI.13 Managing patients with discordant CDI testing results (NAAT positive and toxin negative) represents a significant clinical challenge. Our survey revealed that most physicians consider treating such patients. While ID specialists primarily relied on clinical judgment, PCPs more heavily weighted concurrent antibiotic therapy in their treatment decisions. This variation in approach highlights an important gap in current guidelines, which lack clear consensus on managing these diagnostically ambiguous cases. The challenge is further complicated by the limited control physicians have over the testing algorithms employed by their facilities and must accept institutional or central lab decisions about testing choices. This diagnostic uncertainty, combined with the complexity of multistep testing protocols, creates particular challenges for physicians who encounter CDI less frequently. Balancing the risks of undertreatment against unnecessary antibiotic exposure in NAAT positive and toxin negative patients underscores the importance of developing standardized approaches. Our study findings highlight a need for simplified, standardized diagnostic algorithms that are implementable across practice settings. We also found that PCPs regularly refer patients to GIs or IDs for diagnosis, treatment, or advanced management, and that GIs and IDs cross-refer patients. In a companion survey of patients with CDI, we found that most patients with suspected CDI end up referred to and diagnosed by a GI (data not shown). However, with the reduced availability of traditional banked stool for FMT, referral patterns may evolve. While GIs have historically received the majority of referrals due to the procedural nature of colonoscopic FMT, the emergence of oral FDA-approved donor-derived therapeutics may result in a more balanced distribution of referrals between GIs and IDs. ACG guidelines recommend treating initial CDI in low-risk patients with oral vancomycin, oral fidaxomicin, or oral metronidazole.4 For initially severe cases, oral vancomycin or oral fidaxomicin are recommended. IDSA/SHEA guidelines now recommend the use of the fidaxomicin over vancomycin and metronidazole for initial and recurrent infections.5 This contrasts with ACG guidelines, which do not indicate the preferential use of fidaxomicin due to its higher cost and concerns around insurance coverage and patient accessibility. In our survey, IDs were more familiar with the IDSA/SHEA guidelines5 than GIs or PCPs; they were also most likely to prescribe fidaxomicin and felt it was effective in managing CDI. Our findings clearly identified a need for greater consistency in terms of the content and application of CDI guidelines across physicians and practice settings. The observed differences in guideline adherence between specialists and PCPs likely reflect differential exposure to CDI cases and varying institutional support for guideline implementation, as well as practical constraints such as medication costs and insurance coverage limitations. Development of standardized treatment algorithms will help ensure consistency of CDI management as well as allow incorporation of novel antimicrobials under clinical development, such as ridinilazole14 and ibezapolstat.15 Although antibiotics are used as front-line therapy for CDI, many health-care providers were not aware of guideline recommendations for the concomitant use of biologic therapy in patients at high risk of recurrence.4 A first CDI recurrence occurs in up to 25% of patients with an initial infection and is more common in older immunocompromised patients or those with a severe first infection; up to 65% of patients with a first recurrence will experience another.16 The biologic bezlotoxumab may be considered for the prevention of CDI in patients at high risk of recurrence4,5; however, bezlotoxumab was discontinued by the manufacturer on January 31, 2025 per the FDA.17 Inspired by FMT, donor-derived microbiome therapeutics, including fecal microbiota-jslm (RBX2660)8 and fecal microbiota spores-brpk (SER-109),9 were developed to target the microbiome and prevent recurrent CDI. The FDA approval of RBX2660 in 2022 and SER-109 in 2023 is expected to change the treatment landscape for patients with recurrent CDI. Echoing concerns of survey participants, new American Gastroenterological Association guidelines on fecal microbiota-based therapies recognize the lack of evidence supporting commercially developed donor-derived microbiome therapeutics beyond their approved indication in immunocompetent adults with recurrent CDI.18 Compared to FMT,19 familiarity with newer FDA-approved donor-derived microbiome therapeutics was low across all physicians in our survey (<10% reported “very knowledgeable”). Limited understanding of microbiota-based therapeutics represents a significant barrier to implementing these newer treatment options and reveals a pressing need for targeted education, particularly among PCPs. Our study has some important limitations, including a small sample size, with high response rates from physicians in certain states (eg, CA, NY) and no responses from others (eg, WY, AK), which may reduce the generalizability of our findings. Nevertheless, care was taken to ensure that the survey sample was evenly distributed across the US regions, specialties, and practice settings. This survey was conducted approximately 2 years prior to publication. As the landscape of CDI management is rapidly changing, particularly with the introduction of new FDA-approved therapies, provider attitudes and practice patterns regarding donor-derived microbiome therapeutics may have shifted since the time of data collection. Our survey findings led to additional in-depth roundtable discussions with GI, ID, and PCP participants to better understand practice patterns around the management of CDI; findings from those discussions will be published separately. Conclusion This national survey of physicians who treat patients with CDI revealed important opportunities for education and coordination around the use of guidelines for testing and treatment. The development of standardized diagnostic and treatment algorithms, paired with targeted educational initiatives, particularly for PCPs who see patients with CDI infrequently, may ensure greater consistency in patient management, expanded access to effective treatment options, and improved outcomes for patients with CDI.